Dr. Reddy's Reports Sharp Q4 Profit Decline Amidst One-Off Charges; Full-Year Profit Down 24%

summarizeSummary

Dr. Reddy's Laboratories announced Q4 and full-year FY26 financial results, reporting an 86% YoY drop in Q4 profit after tax and a 24% YoY decline for the full year, heavily impacted by one-off charges. The board also recommended a dividend and appointed an AI expert as an Independent Director.

check_boxKey Events

• Significant Q4 Profit Decline

  Profit after tax for Q4 FY26 plummeted 86% year-over-year to ₹2,201 million, with diluted EPS falling to ₹2.64 from ₹16.94 in Q4 FY25.

• Full-Year Profit Contraction

  For the full fiscal year 2026, profit after tax decreased 24% year-over-year to ₹42,850 million, and diluted EPS dropped to ₹51.42 from ₹67.78 in FY25.

• Major One-Off Charges Impacting Results

  Q4 results were significantly impacted by a ₹4,530 million (USD 50 million) shelf stock adjustment related to Lenalidomide, ₹2,277 million in asset impairments (CAR-T and Eftilagimod Alfa), and ₹1,141 million in VAT liability provisions.

• Modest Full-Year Revenue Growth

  Despite the profit decline, full-year FY26 revenues increased 3.2% year-over-year to ₹335,933 million, driven by growth across key markets except North America.

auto_awesomeAnalysis

Dr. Reddy's Laboratories reported a significant decline in Q4 and full-year profitability, primarily due to substantial one-off charges. While the company highlighted underlying business resilience and growth excluding these specific items, the reported numbers show a sharp contraction in earnings. This financial performance, coupled with the stock trading near its 52-week low, could lead to negative market sentiment. The recommended dividend and the strategic appointment of an AI expert to the board offer some positive counterpoints, but the immediate focus will likely be on the earnings miss.